NCT05166616View on ClinicalTrials.gov

Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 7, 2022

Primary Completion Date

October 28, 2027

Study Completion Date

October 28, 2027

Conditions
Advanced Lung Non-Small Cell CarcinomaLocally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8Stage IIIC Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8Unresectable Lung Non-Small Cell Carcinoma
Interventions
PROCEDURE

Biopsy

Correlative studies

DRUG

Osimertinib

Given PO

DRUG

Triptolide Analog

Given PO

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER